{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:03:29Z","timestamp":1777003409641,"version":"3.51.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>\n            <jats:italic>SF3B1<\/jats:italic> gene mutations are prevalent in myelodysplastic syndrome (MDS) and define a distinct disease subtype. These mutations are associated with dysregulated genes and pathways, offering potential for novel therapeutic approaches. However, the aberrant mRNA alternative splicing landscape in <jats:italic>SF3B1<\/jats:italic>-deficient MDS cells remains underexplored. In this study, we investigated the influence of <jats:italic>SF3B1<\/jats:italic> gene alterations on the pre-mRNA splicing landscape in MDS cells using transcriptomic data from two independent MDS cohorts. we identified over 5000 significant differential alternative splicing events associated with <jats:italic>SF3B1<\/jats:italic> mutation. This work corroborates previous studies, showing significant enrichment of MYC activity and heme metabolism in <jats:italic>SF3B1<\/jats:italic> mutant cells. A key novel finding of this study is the identification of a gene expression signature driven by <jats:italic>SF3B1<\/jats:italic> mutations, centered on protein post-translational modifications. Notably, we discovered aberrant alternative splicing of the tumor suppressor gene <jats:italic>UBA7<\/jats:italic>, leading to significantly reduced gene expression. This dysregulation implicates UBA7 as a critical player in MDS pathogenesis. Importantly, the clinical relevance of this finding is underscored by the observation that low <jats:italic>UBA7<\/jats:italic> gene expression was associated with poor overall survival in chronic lymphocytic leukemia (CLL), another hematological malignancy with frequent <jats:italic>SF3B1<\/jats:italic> mutations. Furthermore, a similar association between low <jats:italic>UBA7<\/jats:italic> gene expression and poor survival outcomes was observed across multiple tumor types in the TCGA database, highlighting the broader implications of UBA7 dysregulation in cancer biology. These findings provide new insights into the mechanisms by which SF3B1 mutations reshape the pre-mRNA splicing landscape and drive disease pathogenesis in MDS. Furthermore, they underscore the potential of UBA7 as a biomarker to stratify SF3B1-mutant MDS and CLL patients, offering a refined approach for risk assessment and highlighting opportunities for targeted therapeutic interventions.<\/jats:p>","DOI":"10.1038\/s41598-025-95738-9","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T18:31:53Z","timestamp":1743273113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of UBA7 expression downregulation in myelodysplastic neoplasm with SF3B1 mutations"],"prefix":"10.1038","volume":"15","author":[{"given":"Sael","family":"Alatawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Othman R.","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuad A.","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim A.","family":"Almazni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alhomidi","family":"Almotiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad M.","family":"Almsned","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"8","key":"95738_CR1","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/ajh.26984","volume":"98","author":"G Garcia-Manero","year":"2023","unstructured":"Garcia-Manero, G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 98(8), 1307\u20131325 (2023).","journal-title":"Am J Hematol"},{"issue":"7","key":"95738_CR2","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/leu.2015.69","volume":"29","author":"I Ganan-Gomez","year":"2015","unstructured":"Ganan-Gomez, I. et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes. Leukemia 29(7), 1458\u20131469 (2015).","journal-title":"Leukemia"},{"issue":"1","key":"95738_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood.V86.1.268.bloodjournal861268","volume":"86","author":"A Raza","year":"1995","unstructured":"Raza, A. et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86(1), 268\u2013276 (1995).","journal-title":"Blood"},{"issue":"22","key":"95738_CR4","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil, E. et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22), 3616\u20133627 (2013) (quiz 3699).","journal-title":"Blood"},{"issue":"18","key":"95738_CR5","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood-2017-02-692715","volume":"129","author":"P Joshi","year":"2017","unstructured":"Joshi, P., Halene, S. & Abdel-Wahab, O. How do messenger RNA splicing alterations drive myelodysplasia?. Blood 129(18), 2465\u20132470 (2017).","journal-title":"Blood"},{"key":"95738_CR6","doi-asserted-by":"publisher","first-page":"100776","DOI":"10.1016\/j.jbior.2020.100776","volume":"79","author":"A Pellagatti","year":"2021","unstructured":"Pellagatti, A. & Boultwood, J. SF3B1 mutant myelodysplastic syndrome: Recent advances. Adv Biol Regul 79, 100776 (2021).","journal-title":"Adv Biol Regul"},{"key":"95738_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2018.07.013","volume":"133","author":"Y Tang","year":"2019","unstructured":"Tang, Y. et al. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis. Crit Rev Oncol Hematol 133, 74\u201383 (2019).","journal-title":"Crit Rev Oncol Hematol"},{"issue":"24","key":"95738_CR8","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","volume":"118","author":"L Malcovati","year":"2011","unstructured":"Malcovati, L. et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms. Blood 118(24), 6239\u20136246 (2011).","journal-title":"Blood"},{"issue":"2","key":"95738_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood.2020004850","volume":"136","author":"L Malcovati","year":"2020","unstructured":"Malcovati, L. et al. SF3B1-mutant MDS as a distinct disease subtype: A proposal from the International Working Group for the Prognosis of MDS. Blood 136(2), 157\u2013170 (2020).","journal-title":"Blood"},{"issue":"12","key":"95738_CR10","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1038\/s41375-022-01728-5","volume":"36","author":"S Huber","year":"2022","unstructured":"Huber, S. et al. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis. Leukemia 36(12), 2894\u20132902 (2022).","journal-title":"Leukemia"},{"issue":"1","key":"95738_CR11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ijc.28011","volume":"133","author":"EM Je","year":"2013","unstructured":"Je, E. M., Yoo, N. J., Kim, Y. J., Kim, M. S. & Lee, S. H. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors. Int J Cancer 133(1), 260\u2013265 (2013).","journal-title":"Int J Cancer"},{"issue":"2","key":"95738_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccell.2018.12.013","volume":"35","author":"S Yin","year":"2019","unstructured":"Yin, S. et al. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of Sf3b1 mutation and atm deletion. Cancer Cell 35(2), 283\u2013296 (2019).","journal-title":"Cancer Cell"},{"issue":"10","key":"95738_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1261\/rna.056101.116","volume":"22","author":"J Qiu","year":"2016","unstructured":"Qiu, J. et al. Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. RNA 22(10), 1535\u20131549 (2016).","journal-title":"RNA"},{"issue":"9","key":"95738_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1101\/gad.278424.116","volume":"30","author":"D Inoue","year":"2016","unstructured":"Inoue, D., Bradley, R. K. & Abdel-Wahab, O. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis. Genes Dev 30(9), 989\u20131001 (2016).","journal-title":"Genes Dev"},{"key":"95738_CR15","doi-asserted-by":"publisher","first-page":"100920","DOI":"10.1016\/j.jbior.2022.100920","volume":"87","author":"A Pellagatti","year":"2023","unstructured":"Pellagatti, A. & Boultwood, J. Splicing factor mutations in the myelodysplastic syndromes: Role of key aberrantly spliced genes in disease pathophysiology and treatment. Adv Biol Regul 87, 100920 (2023).","journal-title":"Adv Biol Regul"},{"issue":"5","key":"95738_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.ccell.2015.04.006","volume":"27","author":"E Kim","year":"2015","unstructured":"Kim, E. et al. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27(5), 617\u2013630 (2015).","journal-title":"Cancer Cell"},{"issue":"5","key":"95738_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ccell.2015.04.008","volume":"27","author":"CL Shirai","year":"2015","unstructured":"Shirai, C. L. et al. Mutant U2AF1 expression alters hematopoiesis and Pre-mRNA splicing in vivo. Cancer Cell 27(5), 631\u2013643 (2015).","journal-title":"Cancer Cell"},{"issue":"12","key":"95738_CR18","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1038\/leu.2016.149","volume":"30","author":"H Dolatshad","year":"2016","unstructured":"Dolatshad, H. et al. Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes. Leukemia 30(12), 2322\u20132331 (2016).","journal-title":"Leukemia"},{"issue":"12","key":"95738_CR19","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood-2018-04-843771","volume":"132","author":"A Pellagatti","year":"2018","unstructured":"Pellagatti, A. et al. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes\/pathways and clinical associations. Blood 132(12), 1225\u20131240 (2018).","journal-title":"Blood"},{"issue":"5","key":"95738_CR20","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/leu.2014.331","volume":"29","author":"H Dolatshad","year":"2015","unstructured":"Dolatshad, H. et al. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia 29(5), 1092\u20131103 (2015).","journal-title":"Leukemia"},{"issue":"1","key":"95738_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29(1), 15\u201321 (2013).","journal-title":"Bioinformatics"},{"issue":"1","key":"95738_CR22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"GA Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. A. et al. From FastQ data to high confidence variant calls: The genome analysis toolkit best practices pipeline. Curr Protoc Bioinform. 43(1), 11 (2013).","journal-title":"Curr Protoc Bioinform."},{"issue":"10","key":"95738_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrg3778","volume":"15","author":"XD Fu","year":"2014","unstructured":"Fu, X. D. & Ares, M. Jr. Context-dependent control of alternative splicing by RNA-binding proteins. Nat Rev Genet 15(10), 689\u2013701 (2014).","journal-title":"Nat Rev Genet"},{"issue":"1","key":"95738_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13059-017-1184-4","volume":"18","author":"R Middleton","year":"2017","unstructured":"Middleton, R. et al. IRFinder: Assessing the impact of intron retention on mammalian gene expression. Genome Biol 18(1), 51 (2017).","journal-title":"Genome Biol"},{"issue":"1","key":"95738_CR25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26(1), 139\u2013140 (2010).","journal-title":"Bioinformatics"},{"issue":"7","key":"95738_CR26","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7), 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"issue":"9","key":"95738_CR27","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1101\/gr.135350.111","volume":"22","author":"J Harrow","year":"2012","unstructured":"Harrow, J. et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res 22(9), 1760\u20131774 (2012).","journal-title":"Genome Res"},{"issue":"12","key":"95738_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12), 550 (2014).","journal-title":"Genome Biol"},{"issue":"43","key":"95738_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43), 15545\u201315550 (2005).","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"95738_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/bioinformatics\/btab561","volume":"38","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. UCSCXenaShiny: an R\/CRAN package for interactive analysis of UCSC Xena data. Bioinformatics 38(2), 527\u2013529 (2022).","journal-title":"Bioinformatics"},{"issue":"14","key":"95738_CR31","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1093\/bioinformatics\/btv034","volume":"31","author":"Y Katz","year":"2015","unstructured":"Katz, Y. et al. Quantitative visualization of alternative exon expression from RNA-seq data. Bioinformatics 31(14), 2400\u20132402 (2015).","journal-title":"Bioinformatics"},{"issue":"6","key":"95738_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2159-8290.CD-19-1330","volume":"10","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. Cancer Discov 10(6), 806\u2013821 (2020).","journal-title":"Cancer Discov"},{"issue":"6","key":"95738_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2643-3230.BCD-21-0220","volume":"3","author":"V Adema","year":"2022","unstructured":"Adema, V. et al. Targeting the EIF2AK1 signaling pathway rescues red blood cell production in SF3B1-mutant myelodysplastic syndromes with ringed sideroblasts. Blood Cancer Discov 3(6), 554\u2013567 (2022).","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"95738_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/leu.2014.170","volume":"29","author":"V Visconte","year":"2015","unstructured":"Visconte, V. et al. Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron. Leukemia 29(1), 188\u2013195 (2015).","journal-title":"Leukemia"},{"issue":"D1","key":"95738_CR35","doi-asserted-by":"publisher","first-page":"D649","DOI":"10.1093\/nar\/gkx1132","volume":"46","author":"A Fabregat","year":"2018","unstructured":"Fabregat, A. et al. The reactome pathway knowledgebase. Nucleic Acids Res 46(D1), D649\u2013D655 (2018).","journal-title":"Nucleic Acids Res"},{"issue":"7778","key":"95738_CR36","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-019-1646-9","volume":"574","author":"D Inoue","year":"2019","unstructured":"Inoue, D. et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature 574(7778), 432\u2013436 (2019).","journal-title":"Nature"},{"key":"95738_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-020-00220-5","volume":"8","author":"Z Zhou","year":"2020","unstructured":"Zhou, Z. et al. The biological function and clinical significance of SF3B1 mutations in cancer. Biomark Res 8, 38 (2020).","journal-title":"Biomark Res"},{"issue":"5","key":"95738_CR38","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.celrep.2015.09.053","volume":"13","author":"RB Darman","year":"2015","unstructured":"Darman, R. B. et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3\u2019 splice site selection through use of a different branch point. Cell Rep 13(5), 1033\u20131045 (2015).","journal-title":"Cell Rep"},{"issue":"11","key":"95738_CR39","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1038\/s41375-024-02379-4","volume":"38","author":"D Hagerstrand","year":"2024","unstructured":"Hagerstrand, D. et al. The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia. Leukemia 38(11), 2429\u20132442 (2024).","journal-title":"Leukemia"},{"issue":"2","key":"95738_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lungcan.2008.05.009","volume":"63","author":"X Yin","year":"2009","unstructured":"Yin, X., Cong, X., Yan, M. & Zhang, D. E. Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer 63(2), 194\u2013200 (2009).","journal-title":"Lung Cancer"},{"issue":"3","key":"95738_CR41","first-page":"163","volume":"4","author":"K Kok","year":"1995","unstructured":"Kok, K. et al. The genomic structure of the human UBE1L gene. Gene Expr 4(3), 163\u2013175 (1995).","journal-title":"Gene Expr"},{"issue":"6","key":"95738_CR42","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O","volume":"85","author":"PM McLaughlin","year":"2000","unstructured":"McLaughlin, P. M. et al. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int J Cancer 85(6), 871\u2013876 (2000).","journal-title":"Int J Cancer"},{"issue":"4","key":"95738_CR43","first-page":"2773","volume":"19","author":"M Lin","year":"2020","unstructured":"Lin, M., Li, Y., Qin, S., Jiao, Y. & Hua, F. Ubiquitin-like modifier-activating enzyme 7 as a marker for the diagnosis and prognosis of breast cancer. Oncol Lett 19(4), 2773\u20132784 (2020).","journal-title":"Oncol Lett"},{"issue":"3","key":"95738_CR44","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","volume":"30","author":"EA Obeng","year":"2016","unstructured":"Obeng, E. A. et al. Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation. Cancer Cell 30(3), 404\u2013417 (2016).","journal-title":"Cancer Cell"},{"issue":"3","key":"95738_CR45","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/leu.2016.251","volume":"31","author":"A Mupo","year":"2017","unstructured":"Mupo, A. et al. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts. Leukemia 31(3), 720\u2013727 (2017).","journal-title":"Leukemia"},{"issue":"5","key":"95738_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/gm451","volume":"5","author":"DA Landau","year":"2013","unstructured":"Landau, D. A. & Wu, C. J. Chronic lymphocytic leukemia: Molecular heterogeneity revealed by high-throughput genomics. Genome Med 5(5), 47 (2013).","journal-title":"Genome Med"},{"issue":"23","key":"95738_CR47","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1182\/blood-2013-02-427641","volume":"121","author":"Y Wan","year":"2013","unstructured":"Wan, Y. & Wu, C. J. SF3B1 mutations in chronic lymphocytic leukemia. Blood 121(23), 4627\u20134634 (2013).","journal-title":"Blood"},{"issue":"9","key":"95738_CR48","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado, J., Nadeu, F., Colomer, D. & Campo, E. Chronic lymphocytic leukemia: From molecular pathogenesis to novel therapeutic strategies. Haematologica 105(9), 2205\u20132217 (2020).","journal-title":"Haematologica"},{"issue":"6","key":"95738_CR49","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41375-020-0714-3","volume":"34","author":"M Quijada-Alamo","year":"2020","unstructured":"Quijada-Alamo, M. et al. CRISPR\/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia 34(6), 1599\u20131612 (2020).","journal-title":"Leukemia"},{"key":"95738_CR50","doi-asserted-by":"crossref","unstructured":"Seiler, M., Peng, S., Agrawal, A. A., Palacino, J., Teng, T., Zhu, P., Smith, P. G., Cancer Genome Atlas Research, N., Buonamici, S., Yu, L. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018, 23(1):282\u2013296.","DOI":"10.1016\/j.celrep.2018.01.088"},{"issue":"5","key":"95738_CR51","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","volume":"30","author":"L Wang","year":"2016","unstructured":"Wang, L. et al. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell 30(5), 750\u2013763 (2016).","journal-title":"Cancer Cell"},{"issue":"9","key":"95738_CR52","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1038\/s41375-020-0753-9","volume":"34","author":"S Singh","year":"2020","unstructured":"Singh, S. et al. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications. Leukemia 34(9), 2525\u20132530 (2020).","journal-title":"Leukemia"},{"issue":"18","key":"95738_CR53","doi-asserted-by":"publisher","first-page":"3583","DOI":"10.1007\/s00018-020-03493-z","volume":"77","author":"C Sun","year":"2020","unstructured":"Sun, C. The SF3b complex: Splicing and beyond. Cell Mol Life Sci 77(18), 3583\u20133595 (2020).","journal-title":"Cell Mol Life Sci"},{"key":"95738_CR54","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fcell.2015.00008","volume":"3","author":"KJ Niklas","year":"2015","unstructured":"Niklas, K. J., Bondos, S. E., Dunker, A. K. & Newman, S. A. Rethinking gene regulatory networks in light of alternative splicing, intrinsically disordered protein domains, and post-translational modifications. Front Cell Dev Biol 3, 8 (2015).","journal-title":"Front Cell Dev Biol"},{"key":"95738_CR55","doi-asserted-by":"crossref","unstructured":"Novak, P., Wang, X., Ellenbecker, M., Feilzer, S., Voronina, E. Splicing machinery facilitates post-transcriptional regulation by FBFs and other RNA-binding proteins in caenorhabditis elegans germline. G3 (Bethesda) 2015, 5(10), 2051\u20132059.","DOI":"10.1534\/g3.115.019315"},{"key":"95738_CR56","doi-asserted-by":"crossref","unstructured":"Mirzalieva, O., Juncker, M., Schwartzenburg, J., Desai, S. ISG15 and ISGylation in human diseases. Cells 2022, 11(3).","DOI":"10.3390\/cells11030538"},{"key":"95738_CR57","doi-asserted-by":"publisher","first-page":"788410","DOI":"10.3389\/fcell.2021.788410","volume":"9","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. ISGylation in innate antiviral immunity and pathogen defense responses: A review. Front Cell Dev Biol 9, 788410 (2021).","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"95738_CR58","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/0008-5472.CAN-05-1123","volume":"66","author":"SD Desai","year":"2006","unstructured":"Desai, S. D. et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin\/26S proteasome pathway. Cancer Res 66(2), 921\u2013928 (2006).","journal-title":"Cancer Res"},{"issue":"4","key":"95738_CR59","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/1535-7163.MCT-07-0515","volume":"7","author":"SJ Shah","year":"2008","unstructured":"Shah, S. J. et al. UBE1L represses PML\/RARalpha by targeting the PML domain for ISG15ylation. Mol Cancer Ther 7(4), 905\u2013914 (2008).","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"95738_CR60","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1158\/1535-7163.MCT-08-0753","volume":"7","author":"Q Feng","year":"2008","unstructured":"Feng, Q. et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther 7(12), 3780\u20133788 (2008).","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"95738_CR61","doi-asserted-by":"publisher","first-page":"7221","DOI":"10.18632\/oncotarget.3372","volume":"6","author":"J Burks","year":"2015","unstructured":"Burks, J., Reed, R. E. & Desai, S. D. Free ISG15 triggers an antitumor immune response against breast cancer: A new perspective. Oncotarget 6(9), 7221\u20137231 (2015).","journal-title":"Oncotarget"},{"issue":"10","key":"95738_CR62","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1038\/s41375-024-02364-x","volume":"38","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Downregulation of UBA1 expression in myelodysplastic neoplasm. Leukemia 38(10), 2284\u20132288 (2024).","journal-title":"Leukemia"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95738-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95738-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:28:20Z","timestamp":1743452900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95738-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95738"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95738-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"19 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Due to the nature of this design, no additional ethical approval was needed. Consequently, the Local Ethics Committee waived the ethical approval. This study analyzed publicly available data from multiple independent cohorts (GSE114922 and GSE63569 for MDS, CLL-ES for CLL from ICGC, and cancer cohorts from the TCGA database).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"10856"}}